<DOC>
	<DOC>NCT00500500</DOC>
	<brief_summary>The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>female or male of 50 to 85 years old with a care giver Mini Mental Status (MMS) test between 16 to 26 inclusive Clinical Dementia Rating (CDR) test inferior or equal to 1 National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for an Alzheimer's disease Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test positive for dementia patient already treated by medicines which could interfere with the study low level of vitamin B12 and folate which are considered as clinically relevant clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness….)</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>